Dec 17, 2017

NEW YORK, December 12, 2017 –CLS-Therapeutics, Inc. (“CLS”), a biopharmaceutical company dedicated to developing and commercializing novel anticancer gene therapy technology, announced the initiation of Proof of concept in animal cancer models at the Uppsala Universityofthe company’s lead candidate CLS-D1. CLS-D1 is a gene therapeutic agent, with targeted mechanism of action, which is exerted through destruction of circulating cfDNA by a gene therapy-delivered DNase I enzyme.